modelDesvenlafaxine
Extends from Pharmacolibrary.Drugs.ATC.N.N06AX23.
Information
| name: | Desvenlafaxine | |
| ATC code: | N06AX23 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 3.4 | L |
| clearance: | 11 | L/hr |
| other parameters in model implementation | ||
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used in the treatment of major depressive disorder (MDD) in adults. It is approved by the FDA and marketed under the brand name Pristiq.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects after oral administration of a 100 mg tablet.
References
Nichols, AI, et al., & Abbas, R (2018). Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. Clinical pharmacology in drug development 7(4) 441–450. DOI:10.1002/cpdd.419 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29228473
Dolder, C, et al., & Stump, A (2010). Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs & aging 27(8) 625–640. DOI:10.2165/11537140-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20658791
Chen, YX, et al., & Zhong, DF (2015). [The enantioselective pharmacokinetic study of desvenlafaxine sustained release tablet in Chinese healthy male volunteers after oral administration]. Yao xue xue bao = Acta pharmaceutica Sinica 50(4) 486–491. PUBMED:https://pubmed.ncbi.nlm.nih.gov/26223133
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)